Kos Pharmaceuticals Reports New Research Presented At AHA: Raising HDL-C Or ''Good’’ Cholesterol With Niaspan(R) Reverses Atherosclerosis

DALLAS--(BUSINESS WIRE)--Nov. 15, 2005--Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): Definite Atherosclerosis Regression 12-24 Months Following Treatment With Niaspan. Results Reinforce Benefit of Raising HDL-C in Patients With Well-Controlled LDL-C Levels. Sustained Increases in HDL-C Independently Associated With Superior Effects on Atherosclerosis Regression.